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backgound: In patients taking dual antiplatelet therapy with acetylsalycilic acid (ASA) and clopidogrel, proton-pump inhibitors are often utilized 
for gastrointestinal (GI) bleeding prophylaxis. However, this class of medication has been associated with reduction of the antiplatelet potency of 
clopidogrel. The main purpose of this study was to compare the antiplatelet effect of clopidogrel taken with ranitidine or omeprazole.
methods: We analyzed 85 patients with chronic coronary artery disease (CAD) treated with ASA 100 mg QOD chronically. All patients had their 
platelet aggregability measured after one week of clopidogrel 75 mg daily. VerifyNow P2Y12TM was utilized, with aggregability depicted as P2Y12 
Reactivity Units (PRU). In the sequence, the subjects were randomized to receive, in a double-blind, double-dummy fashion, omeprazole 20 mg BID 
or ranitidine 150 mg BID. After one more week of treatment, the aggregability test was repeated.
results: The median age of the population was 63 y (67 % males). Forty-one patients were randomized to omeprazole and 44 to ranitidine, being 
the groups well matched. The mean platelet aggregability before GI prophylaxis in the global population was 157,87 ± 76,75 PRU. The results after 
one week of treatment in both groups are depicted in the table.
conclusion: In patients with stable CAD treated with ASA, ranitidine did not influence the clopidogrel antiplatelet activity, contrary to omeprazole 
utilization that reduced the antiplatelet drug activity.
Results: Mean ± SD platelet aggregability
Ranitidine (n = 44) Omeprazole (n = 41)
Baseline PRU (with only ASA + clopidogrel) 153,61 ± 70,12 159,73 ± 83,06
PRU after one week of study drug treatment 158,77 ± 76,37 173,54 ± 72,29
P-value 0,44 0,043
